We are live on
!
Find out more
Lineage Cell Therapeutics
LCTX
LCTX
104 hedge funds and large institutions have $89.1M invested in Lineage Cell Therapeutics in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 26 increasing their positions, 24 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
8% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 24
1.3% less ownership
Funds ownership: 44.45% → 43.15% (-1.3%)
3% less funds holding
Funds holding: 107 → 104 (-3)
16% less capital invested
Capital invested by funds: $107M → $89.1M (-$17.5M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Holders
104
Holders Change
-3
Holders Change %
-2.8%
% of All Funds
1.65%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
6
Increased
26
Reduced
24
Closed
9
Calls
$64K
Puts
–
Net Calls
+$64K
Net Calls Change
+$16K
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.57M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$471K |
| 3 |
BlackRock
New York
|
+$375K |
| 4 |
Morgan Stanley
New York
|
+$171K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$137K |
Top Sellers
| 1 |
LCM
Laurion Capital Management
New York
|
-$1.13M |
| 2 |
HF
HRT Financial
New York
|
-$1.05M |
| 3 |
JP Morgan Chase
New York
|
-$450K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$197K |
| 5 |
Two Sigma Investments
New York
|
-$115K |
